>Amgen, Inc.
Date Filed: June 5, 2007
Court: U.S. District Court
Location: California
Ticker Symbol: AMGN
Hagens Berman Sobol Shapiro has filed a proposed nationwide class-action lawsuit against drug manufacturer Amgen, Inc. (NASDAQ:AMGN) alleging the company acted unlawfully in the off-label and deceptive marketing of its drug products known as erythropoiesis-stimulating agents (ESA) drugs, under brand names Epogen® and Aranesp®.
According to the filed complaint Epogen and Aranesp are approved for use with kidney and cancer patients to boost hemoglobin levels and prevent patients from needing a blood transfusion.
The lawsuit was filed on behalf of patients who have paid for these drugs where the defendant allegedly marketed the products outside of the bounds of their FDA approvals. According to the complaint as a result of these practices the plaintiff paid for ESAs when they would not have otherwise done so.
If you or anyone you know has been taking Epogen or Aranesp please click here to see if you qualify to join the class.
Hagens Berman Sobol Shapiro will keep all information received as confidential and will not share it with third parties.
You can also send us an e-mail at info@hbsslaw.com or call our office at 206-623-7292.
Court: U.S. District Court
Location: California
Ticker Symbol: AMGN
Hagens Berman Sobol Shapiro has filed a proposed nationwide class-action lawsuit against drug manufacturer Amgen, Inc. (NASDAQ:AMGN) alleging the company acted unlawfully in the off-label and deceptive marketing of its drug products known as erythropoiesis-stimulating agents (ESA) drugs, under brand names Epogen® and Aranesp®.
According to the filed complaint Epogen and Aranesp are approved for use with kidney and cancer patients to boost hemoglobin levels and prevent patients from needing a blood transfusion.
The lawsuit was filed on behalf of patients who have paid for these drugs where the defendant allegedly marketed the products outside of the bounds of their FDA approvals. According to the complaint as a result of these practices the plaintiff paid for ESAs when they would not have otherwise done so.
If you or anyone you know has been taking Epogen or Aranesp please click here to see if you qualify to join the class.
Hagens Berman Sobol Shapiro will keep all information received as confidential and will not share it with third parties.
You can also send us an e-mail at info@hbsslaw.com or call our office at 206-623-7292.
| SHARE: |
|
Cases and Investigations
| CONTACT US | CYCLING TEAM | INSTITUTIONAL INVESTORS | FOLLOW US ONLINE: |
|
|
Sign Up For E-Mail Alerts